Who are Inpegsomatropin Injection's main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): PEG-rhGH Injection + Semaglutide Injection, Saizen® A, TH9507, DA-3801 Injection, GenSci004, GenSci094.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/inpegsomatropin-injection.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-05-16 · How we verify

Inpegsomatropin Injection — Competitive Intelligence Brief

Inpegsomatropin Injection (Inpegsomatropin Injection) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Growth hormone analog. Area: Endocrinology.

phase 3 Growth hormone analog Growth hormone receptor (GHR) Endocrinology Small molecule Live · refreshed every 30 min

Target snapshot

Inpegsomatropin Injection (Inpegsomatropin Injection) — Xiamen Amoytop Biotech Co., Ltd.. Inpegsomatropin is a long-acting growth hormone analog that binds to growth hormone receptors to promote growth, metabolism, and body composition changes.

Comparator set (6 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target
Inpegsomatropin Injection TARGET	Inpegsomatropin Injection	Xiamen Amoytop Biotech Co., Ltd.	phase 3	Growth hormone analog	Growth hormone receptor (GHR)
PEG-rhGH Injection + Semaglutide Injection	PEG-rhGH Injection + Semaglutide Injection	Shanghai Zhongshan Hospital	marketed	Growth hormone analog + GLP-1 receptor agonist combination	Growth hormone receptor; GLP-1 receptor
Saizen® A	Saizen® A	Merck KGaA, Darmstadt, Germany	phase 3	Growth hormone analogue	Growth hormone receptor
TH9507	TH9507	Theratechnologies	phase 3	Growth hormone analog	Growth hormone receptor (GHR)
DA-3801 Injection	DA-3801 Injection	Dong-A ST Co., Ltd.	phase 3	Growth hormone analog	Growth hormone receptor
GenSci004	GenSci004	Changchun GeneScience Pharmaceutical Co., Ltd.	phase 3	Growth hormone analog	Growth hormone receptor
GenSci094	GenSci094	Changchun GeneScience Pharmaceutical Co., Ltd.	phase 3	Growth hormone analog	Growth hormone receptor

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Growth hormone analog class)

Changchun GeneScience Pharmaceutical Co., Ltd. · 2 drugs in this class
Ascendis Pharma A/S · 1 drug in this class
Dong-A ST Co., Ltd. · 1 drug in this class
Theratechnologies · 1 drug in this class
Xiamen Amoytop Biotech Co., Ltd. · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Inpegsomatropin Injection — Competitive Intelligence Brief. https://druglandscape.com/ci/inpegsomatropin-injection. Accessed 2026-05-16.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab